Search Results - "Shah, Nisargbhai S S."

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer by Wohlhieter, Corrin A., Richards, Allison L., Uddin, Fathema, Hulton, Christopher H., Quintanal-Villalonga, Àlvaro, Martin, Axel, de Stanchina, Elisa, Bhanot, Umeshkumar, Asher, Marina, Shah, Nisargbhai S., Hayatt, Omar, Buonocore, Darren J., Rekhtman, Natasha, Shen, Ronglai, Arbour, Kathryn C., Donoghue, Mark, Poirier, John T., Sen, Triparna, Rudin, Charles M.

“…Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma (LUAD) are associated with aggressive tumor growth, resistance to available…”
Get full text

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC by Taniguchi, Hirokazu, Caeser, Rebecca, Chavan, Shweta S., Zhan, Yingqian A., Chow, Andrew, Manoj, Parvathy, Uddin, Fathema, Kitai, Hidenori, Qu, Rui, Hayatt, Omar, Shah, Nisargbhai S., Quintanal Villalonga, Álvaro, Allaj, Viola, Nguyen, Evelyn M., Chan, Joseph, Michel, Adam O., Mukae, Hiroshi, de Stanchina, Elisa, Rudin, Charles M., Sen, Triparna

“…Small cell lung cancers (SCLCs) have high mutational burden but are relatively unresponsive to immune checkpoint blockade (ICB). Using SCLC models, we…”
Get full text

Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts by Caeser, Rebecca, Egger, Jacklynn V., Chavan, Shweta, Socci, Nicholas D., Jones, Caitlin Byrne, Kombak, Faruk Erdem, Asher, Marina, Roehrl, Michael H., Shah, Nisargbhai S., Allaj, Viola, Manoj, Parvathy, Tischfield, Sam E., Kulick, Amanda, Meneses, Maximiliano, Iacobuzio-Donahue, Christine A., Lai, W. Victoria, Bhanot, Umeshkumar, Baine, Marina K., Rekhtman, Natasha, Hollmann, Travis J., de Stanchina, Elisa, Poirier, John T., Rudin, Charles M., Sen, Triparna

“…Access to clinically relevant small cell lung cancer (SCLC) tissue is limited because surgical resection is rare in metastatic SCLC. Patient-derived xenografts…”
Get full text

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation by Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Zhan, Yingqian A, Hasan, Maysun M, Chavan, Shweta S, Meng, Fanli, Uddin, Fathema, Allaj, Viola, Manoj, Parvathy, Shah, Nisargbhai S, Chan, Joseph M, Ciampricotti, Metamia, Chow, Andrew, Offin, Michael, Ray-Kirton, Jordana, Egger, Jacklynn D, Bhanot, Umesh K, Linkov, Irina, Asher, Marina, Roehrl, Michael H, Ventura, Katia, Qiu, Juan, de Stanchina, Elisa, Chang, Jason C, Rekhtman, Natasha, Houck-Loomis, Brian, Koche, Richard P, Yu, Helena A, Sen, Triparna, Rudin, Charles M

“…Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung…”
Get full text

Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library by Offin, Michael, Sauter, Jennifer L, Tischfield, Sam E, Egger, Jacklynn V, Chavan, Shweta, Shah, Nisargbhai S, Manoj, Parvathy, Ventura, Katia, Allaj, Viola, de Stanchina, Elisa, Travis, William, Ladanyi, Marc, Rimner, Andreas, Rusch, Valerie W, Adusumilli, Prasad S, Poirier, John T, Zauderer, Marjorie G, Rudin, Charles M, Sen, Triparna

“…Diffuse pleural mesothelioma (DPM) is an aggressive malignancy that, despite recent treatment advances, has unacceptably poor outcomes. Therapeutic research in…”
Get full text

MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer by Caeser, Rebecca, Hulton, Christopher, Costa, Emily, Durani, Vidushi, Little, Megan, Chen, Xiaoping, Tischfield, Sam E., Asher, Marina, Kombak, Faruk Erdem, Chavan, Shweta S., Shah, Nisargbhai S., Ciampricotti, Metamia, de Stanchina, Elisa, Poirier, John T., Rudin, Charles M., Sen, Triparna

“…Activation of mitogenic signaling pathways is a common oncogenic driver of many solid tumors including lung cancer. Although activating mutations in the…”
Get full text

Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity by Chow, Andrew, Schad, Sara, Green, Michael D., Hellmann, Matthew D., Allaj, Viola, Ceglia, Nicholas, Zago, Giulia, Shah, Nisargbhai S., Sharma, Sai Kiran, Mattar, Marissa, Chan, Joseph, Rizvi, Hira, Zhong, Hong, Liu, Cailian, Bykov, Yonina, Zamarin, Dmitriy, Shi, Hongyu, Budhu, Sadna, Wohlhieter, Corrin, Uddin, Fathema, Gupta, Aditi, Khodos, Inna, Waninger, Jessica J., Qin, Angel, Markowitz, Geoffrey J., Mittal, Vivek, Balachandran, Vinod, Durham, Jennifer N., Le, Dung T., Zou, Weiping, Shah, Sohrab P., McPherson, Andrew, Panageas, Katherine, Lewis, Jason S., Perry, Justin S.A., de Stanchina, Elisa, Sen, Triparna, Poirier, John T., Wolchok, Jedd D., Rudin, Charles M., Merghoub, Taha

“…Immune checkpoint blockade (ICB) has been a remarkable clinical advance for cancer; however, the majority of patients do not respond to ICB therapy. We show…”
Get full text

Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC by Nguyen, Evelyn M, Taniguchi, Hirokazu, Chan, Joseph M, Zhan, Yingqian A, Chen, Xiaoping, Qiu, Juan, de Stanchina, Elisa, Allaj, Viola, Shah, Nisargbhai S, Uddin, Fathema, Manoj, Parvathy, Liu, Michael, Cai, Sheng F, Levine, Ross, Quintanal-Villalonga, Álvaro, Sen, Triparna, Chow, Andrew, Rudin, Charles M

“…SCLC is a highly aggressive neuroendocrine tumor that is characterized by early acquired therapeutic resistance and modest benefit from immune checkpoint…”
Get more information

Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy by Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Hao, Yuan, Chow, Andrew, Zhan, Yingqian A, Chavan, Shweta S, Uddin, Fathema, Allaj, Viola, Manoj, Parvathy, Shah, Nisargbhai S, Chan, Joseph M, Offin, Michael, Ciampricotti, Metamia, Ray-Kirton, Jordana, Egger, Jacklynn, Bhanot, Umesh, Linkov, Irina, Asher, Marina, Roehrl, Michael H, Qiu, Juan, de Stanchina, Elisa, Hollmann, Travis J, Koche, Richard P, Sen, Triparna, Poirier, John T, Rudin, Charles M

“…Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past…”
Get full text

Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers by Quintanal-Villalonga, Alvaro, Durani, Vidushi, Sabet, Amin, Redin, Esther, Kawasaki, Kenta, Shafer, Moniquetta, Karthaus, Wouter R, Zaidi, Samir, Zhan, Yingqian A, Manoj, Parvathy, Sridhar, Harsha, Shah, Nisargbhai S, Chow, Andrew, Bhanot, Umesh K, Linkov, Irina, Asher, Marina, Yu, Helena A, Qiu, Juan, de Stanchina, Elisa, Patel, Radhika A, Morrissey, Colm, Haffner, Michael C, Koche, Richard P, Sawyers, Charles L, Rudin, Charles M

“…In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an aggressive derivative resembling small cell lung cancer (SCLC) is associated…”
Get more information

Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics by Hulton, Christopher H, Costa, Emily A, Shah, Nisargbhai S, Quintanal-Villalonga, Alvaro, Heller, Glenn, de Stanchina, Elisa, Rudin, Charles M, Poirier, John T

“…Patient-derived xenografts are high fidelity tumor models that accurately reflect many key aspects of human cancer. In contrast to either cancer cell lines or…”
Get full text

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer by Taniguchi, Hirokazu, Chakraborty, Subhamoy, Takahashi, Nobuyuki, Banerjee, Avisek, Caeser, Rebecca, Zhan, Yingqian A, Tischfield, Sam E, Chow, Andrew, Nguyen, Evelyn M, Villalonga, Álvaro Quintanal, Manoj, Parvathy, Shah, Nisargbhai S, Rosario, Samantha, Hayatt, Omar, Qu, Rui, de Stanchina, Elisa, Chan, Joseph, Mukae, Hiroshi, Thomas, Anish, Rudin, Charles M, Sen, Triparna

“…Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience only transient benefits from combined immune checkpoint blockade (ICB)…”
Get full text

Abstract LB186: MAPK pathway activation represents a therapeutic vulnerability in ASCL1 -driven SCLC by Caeser, Rebecca, Hulton, Christopher, Durani, Vidushi, Costa, Emily, Little, Megan, Shah, Nisargbhai S., de Stanchina, Elisa, Poirier, John T., Rudin, Charles M., Sen, Triparna

“…Abstract Background Lung cancer is the leading cause of cancer death, killing more people than colon, breast, and prostate cancers combined (Siegel et al…”
Get full text

Abstract 3858: Exploring Exportin-1 as a therapeutic vulnerability in squamous cell carcinoma by Durani, Vidushi, Caeser, Rebecca, Rudin, Charles M., Quintanal-Villalonga, Alvaro, Sridhar, Harsha, Manoj, Parvathy, Tischfield, Sam E., Asher, Marina, Bhanot, Umeshkumar, Egger, Jacklynn V., Socci, Nicholas D. Socci D., Shah, Nisargbhai S S., de Stanchina, Elisa, Rekhtman, Natasha

“…Abstract Introduction: Squamous cell carcinomas (LUSCs) account for 25-30% cases of non-small cell lung cancers, making them the second most common histology…”
Get full text

Abstract 3594: Exportin 1 inhibition as a therapeutic strategy for small cell lung cancer by Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Hao, Yuan, Chow, Andrew, Zhan, Yingqian A., Uddin, Fathema, Allaj, Viola, Manoj, Parvathy, Shah, Nisargbhai S., Bhanot, Umesh K., Qiu, Juan, de Stanchina, Elisa, Koche, Richard P., Sen, Triparna, Poirier, John T., Rudin, Charles M.

“…Abstract Small cell lung cancer (SCLC) is an aggressive disease characterized by early metastasis and exceptional lethality, comprising 13% of all lung cancer…”
Get full text

Abstract 90: STAT3-driven MAPK activation represents a therapeutic vulnerability in ASCL1 high SCLC by Caeser, Rebecca, Hulton, Christopher, Costa, Emily, Durani, Vidushi, Little, Megan, Chen, Xiaoping, Tischfield, Sam E., Asher, Marina, Kombak, Faruk Erdem, Chavan, Shweta S., Shah, Nisargbhai S., Ciampricotti, Metamia, de Stanchina, Elisa, Poirier, John T., Rudin, Charles M., Sen, Triparna

“…Abstract Background Small cell lung cancer (SCLC) is an aggressive high grade neuroendocrine tumor (Hann et al. 2019; Bernhardt et al. 2016). Whilst MAPK…”
Get full text

Abstract 658: AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation by Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Zhan, Yingqian A., Uddin, Fathema, Allaj, Viola, Manoj, Parvathy, Shah, Nisargbhai S., Bhanot, Umesh K., Egger, Jacklynn, Qiu, Juan, de Stanchina, Elisa, Rekhtman, Natasha, Houck-Loomis, Brian, Koche, Richard P., Yu, Helena A., Sen, Triparna, Rudin, Charles M.

“…Abstract Lineage plasticity contributes to therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon drives neuroendocrine (NE) and…”
Get full text